90723-71-0

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Dichloro-4-methylquinoline is used as a key intermediate in the synthesis of various pharmaceuticals, leveraging its unique chemical structure and potential biological activities. Its antimicrobial and antitumor properties contribute to the development of new drugs targeting a wide range of diseases and conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 2,6-Dichloro-4-methylquinoline serves as an essential component in the production of various agrochemicals. Its incorporation aids in the development of effective pesticides, herbicides, and other agricultural chemicals that protect crops and enhance agricultural productivity.
Used in Dye and Pigment Industry:
2,6-Dichloro-4-methylquinoline is utilized as an intermediate in the manufacturing process of dyes and pigments. Its chemical properties enable the creation of a diverse range of colorants used in various industries, including textiles, plastics, and printing inks.
Used in Organic Compounds Synthesis:
As a substituted quinoline, 2,6-Dichloro-4-methylquinoline plays a crucial role in the synthesis of other organic compounds. Its unique structure allows for the development of new chemical entities with potential applications in various fields, such as materials science, chemical research, and the creation of novel functional materials.

InChI:InChI=1/C10H7Cl2N/c1-6-4-10(12)13-9-3-2-7(11)5-8(6)9/h2-5H,1H3

Upstream product

• 20139-55-3 N-(2-methyl-4-chlorophenyl)-3-oxobutanamide 
• 101-92-8 4'-Chloroacetoacetanilide 
• 2585-04-8 6-chloro-4-methyl-quinolin-2-ol 
• 104678-53-7 2,6-dichloro-4-methyl-4-nitrocyclohexa-2,5-dienone 
• 64-19-7 acetic acid 

Downstream Products

• 61305-55-3 4-acetoxy-2,6-dichloro-4-methyl-cyclohexa-2,5-dienone 
• 21703-54-8 2-hydrazino-6-chloro-4-methylquinoline 
• 108936-72-7 6-Chloro-2-(3,5-dimethyl-pyrazol-1-yl)-4-methyl-quinoline 
• 860297-19-4 benzyl {(1S,3S)-3-[benzyloxycarbonyl-(6-chloro-4-methylquinolin-2-yl)amino]cyclohexyl}carbamate 
• 1315380-22-3 6-chloro-4-methyl-2-(4'-methyl-phenylamino)quinoline 
• 1315380-28-9 2-(9-chloro-2-methyl-12-phenyldibenzo[b,g][1,8]naphthyridin-11(6H)-ylidene)-1-phenylethanone 
• 10562-10-4 6-chloro-4-methyl-2-(4'-chloro-phenylamino)quinoline 
• 1315380-18-7 2-(2,9-dichloro-12-phenyldibenzo[b,g][1,8]naphthyridin-11(6H)-ylidene)-1-phenylethanone 
• 1315380-02-9 2[(2'-benzoyl-4'-chlorophenyl)amino]-6-chloro-4-methylquinoline 
• 1448586-48-8 C₃₇H₄₅ClN₆O₄S 

Relevant academic research and scientific papers

Free energy perturbation guided Synthesis with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC)

Two different schemes of novel substituted quinoline derivatives were designed and synthesized via simple reaction steps and conditions. A comparative molecular docking study was carried out on two different types of EGFR enzymes which include wild-type (PDB: 4I23) and T790M mutated (PDB: 2JIV) respectively. Compounds were also validated upon T790M/C797S mutated (PDB ID: 5D41) EGFR enzyme at the allosteric binding site. Free energy perturbations were carried out to determine the absolute binding free energy of a protein–ligand complex in the form of ΔGbinding, which in turn provided 4ab and 5ad as the most potential contenders through the structural enhancement in the determined initial scaffolds. Anticancer activity of the synthesized derivatives was examined against HCC827, H1975 (L858R/T790M), A549, and HT-29 cell lines by standard MTT assay. Compound 4ad (6-chloro-2-(isoindolin-2-yl)-4-methylquinoline) has shown excellent inhibitory activities against mutant EGFR kinase with IC50 value 0.91 μM. The potency of compounds 4ab, 4ad and 5ad was compared through an insilico ADMET study.

Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC)

New substituted quinoline derivatives were designed and synthesized via a five-step modified Suzuki coupling reaction. A comparative molecular docking study was carried out on two different types of EGFR enzymes which include wild-type (PDB: 4I23) and T790M mutated (PDB: 2JIV) respectively. Compounds were also validated upon T790M/C797S mutated (PDB ID: 5D41) EGFR enzyme at the allosteric binding site. All docking studies confirmed high potency and flexibility towards wild type as well as a mutated enzyme. Anticancer activity of the synthesized derivatives was examined against HCC827, H1975 (L858R/T790M/C797S and L858R/T790M), A549, and HT-29 cell lines by standard MTT assay. Most of the quinoline derivatives revealed a significant cytotoxic effect. The IC50 values of 4-(4-methylquinolin-2-yl)phenyl 4-(chloromethyl)benzoate (5j) were found to be 0.0042 μM, 0.02 μM, 1.91 μM, 3.82 μM and 3.67 μM while IC50 values of osimertinib were 0.0040 μM, 0.02 μM, ND, 0.99 μM and 1.22 μM, respectively. Compound 5j has shown excellent inhibitory activities against EGFR kinases triple mutant with IC 50 value 1.91 μM. It was observed that, compared to H1975, A549 and A431 cell lines, synthesized compounds significantly inhibited proliferation of the HCC827 cell line. These data suggested that synthesized compounds showed promising selective anticancer activity against tumor cells harboring EGFR Del E746-A750. The potency of compound 5j was compared through molecular dynamic simulations and an insilico ADMET study. QSAR models were generated and the best model was correctly compared with respect to predicted and observed activity of compounds. The built model will assist to design, refine and construct novel substituted quinoline derivatives as potent EGFR inhibitors in near future.

Compounds having anticonvulsion activity, preparing methods thereof and applications of the compounds

The invention provides 7-substituted-5-methyl-1,2,4-triazolo[4,3-a] quinoline and 7-substituted-5-ethoxy-[1,2,4]-triazolo[4,3-a] quinoline compounds having anticonvulsion activity, preparing methods thereof and applications of the compounds in the field of preparing anticonvulsion medicines.